ReviewDrug design, development and therapy2026
From Single Genes to Systemic Networks: Transcriptomic Insights into Traditional Chinese Medicine for Heart Failure.
Review in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure (HF) represents the terminal stage of diverse cardiovascular pathologies and has emerged as a global public health crisis, characterized by increasing prevalence and persistently poor long-term prognosis. Although modern pharmacological therapies have advanced considerably, high rates of disease recurrence and recurrent hospitalizations continue to profoundly impair patients' quality of life. Traditional Chinese medicine (TCM) has been reported in preclinical and some clinical studies to offer potential benefits, particularly in enhancing cardiac function, alleviating clinical symptoms, and slowing disease progression. Numerous TCM compound formulations are commonly used in clinical practice in China and are gradually attracting international research attention. Nevertheless, the inherent complexity of TCM compositions, their multi-target mechanisms of action, and the lack of clarity regarding their molecular underpinnings remain substantial obstacles to broader acceptance within contemporary medicine. In recent years, driven by the rapid evolution of high-throughput sequencing technologies, transcriptomics has become a pivotal tool in TCM research, facilitating the exploration of disease mechanisms and drug targets. This narrative review synthesizes research progress on TCM interventions for HF from a transcriptomic perspective. It traces the development of major transcriptomic technologies, critically evaluates their respective strengths and limitations, and synthesizes current findings on how TCM modulates differentially expressed genes, signaling pathways, and cellular processes at multiple regulatory levels. Furthermore, it examines the potential therapeutic impact of TCM on key pathological pathways, including myocardial remodeling, energy metabolism dysregulation, and inflammatory responses. By identifying existing research gaps and outlining future directions, this review seeks to elucidate the mechanisms of TCM treatment for HF through modern scientific frameworks, thereby offering novel insights for addressing this challenging condition.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.